Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma

Pediatric Blood and Cancer

Volumn 55, Issue 6, 2010, Pages 1217-1220

  Walsh, Alexandra ^a   Kelly, David R ^b   Vaid, Yoginder N ^b   Hilliard, Lee M ^a   Friedman, Gregory K ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Carboplatin; Gemcitabine; Paclitaxel; Renal medullary carcinoma

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; AZITHROMYCIN; CARBOPLATIN; CYTOKERATIN; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; EPITHELIAL MEMBRANE ANTIGEN; GEMCITABINE; IBUPROFEN; ONDANSETRON; PACLITAXEL; URIC ACID; VIMENTIN;

ABNORMAL RESPIRATORY SOUND; ACETABULUM; ADVANCED CANCER; ARTICLE; BACKACHE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLONAL VARIATION; COMPUTER ASSISTED TOMOGRAPHY; COORDINATION DISORDER; COUGHING; CYTOPLASM; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMUR HEAD; FEVER; FOOTBALL; GENETIC ANALYSIS; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILIAC BONE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFECTION; ISCHIUM; KARYOTYPE 46,XY; KIDNEY; KIDNEY CARCINOMA; KIDNEY MEDULLARY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LUNG NODULE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDULLARY CARCINOMA; MENINGEAL METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NECK; NEPHRECTOMY; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEAT PROCEDURE; RIB; SACRUM; SCHOOL CHILD; SICKLE CELL TRAIT; SPORT INJURY; STERNUM; SWELLING; THORACOSCOPY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, RENAL CELL; CHILD; DEOXYCYTIDINE; HUMANS; KIDNEY NEOPLASMS; MALE; PACLITAXEL; SICKLE CELL TRAIT; TREATMENT OUTCOME;

EID: 77958537003     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22611     Document Type: Article

References (15)

1. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, et al. The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 1995; 121: 478-486.
2. Davis CJ, Jr. Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995; 19: 1-11.
3. Avery RA, Harris JE, Davis CJ, Jr., et al. Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor. Cancer 1996; 78: 128-132.
4. Watanabe IC, Billis A, Guimaraes MS, et al. Renal medullary carcinoma: Report of seven cases from Brazil. Mod Pathol 2007; 20: 914-920.
5. Stahlschmidt J, Cullinane C, Roberts P, et al. Renal medullary carcinoma: Prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med Pediatr Oncol 1999; 33: 551-557.
6. Simpson L, He X, Pins M, et al. Renal medullary carcinoma and ABL gene amplification. J Urol 2005; 173: 1883-1888.
7. Yang XJ, Sugimura J, Tretiakova MS, et al. Gene expression profiling of renal medullary carcinoma: Potential clinical relevance. Cancer 2004; 100: 976-985.
8. Albadine R, Wang W, Brownlee NA, et al. Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol 2009; 82: 735-740.
9. Cheng, J.X., Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol 2008; 21: 647-652.
10. Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: The Bronx experience. Urology 2007; 70: 878-882.
11. Selby DM, Simon C, Foley JP, et al. Renal medullary carcinoma: Can early diagnosis lead to long-term survival? J Urol 2000; 163: 1238.
12. Rathmell WK, Monk JP. High-dose-intensity MVAC for advanced renal medullary carcinoma: Report of three cases and literature review. Urology 2008; 72: 659-663.
13. Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005; 44: 407-411.
14. Bell MD. Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma. Pediatr Blood Cancer 2006; 47: 228.
15. Ronnen BA, Kondagunta GV, Motzer RJ., Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006; 24: e14.